Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform

Core Viewpoint - Xenetic Biosciences, Inc. has announced a 4-month extension of its collaboration with The Scripps Research Institute to advance its research program on combining systemic DNase I and CAR T-cell therapies for cancer treatment [1] Company Summary - The collaboration with Scripps Research and Dr. Alexey Stepanov is effective from November 1, 2025 [1] - Xenetic's systemic DNase I candidate, XBIO-015, is currently in preclinical development [1] - The focus of the development is on the combination of XBIO-015 with CAR-T cell therapy for both hematologic and solid tumors [1]